These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 12850530)

  • 1. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
    Bellmunt J; Hussain M; Dinney CP
    Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S85-104. PubMed ID: 12850530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies in bladder cancer--an update.
    Black PC; Agarwal PK; Dinney CP
    Urol Oncol; 2007; 25(5):433-8. PubMed ID: 17826665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.
    Tiseo M; Loprevite M; Ardizzoni A
    Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):139-48. PubMed ID: 15032719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecularly targeted therapy for gastrointestinal cancer.
    Wiedmann MW; Caca K
    Curr Cancer Drug Targets; 2005 May; 5(3):171-93. PubMed ID: 15892618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.
    Press MF; Lenz HJ
    Drugs; 2007; 67(14):2045-75. PubMed ID: 17883287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ErbB receptor family: a therapeutic target for cancer.
    de Bono JS; Rowinsky EK
    Trends Mol Med; 2002; 8(4 Suppl):S19-26. PubMed ID: 11927283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
    Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
    Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why the epidermal growth factor receptor? The rationale for cancer therapy.
    Baselga J
    Oncologist; 2002; 7 Suppl 4():2-8. PubMed ID: 12202782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.
    Inoue K; Slaton JW; Perrotte P; Davis DW; Bruns CJ; Hicklin DJ; McConkey DJ; Sweeney P; Radinsky R; Dinney CP
    Clin Cancer Res; 2000 Dec; 6(12):4874-84. PubMed ID: 11156247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE).
    Highshaw RA; McConkey DJ; Dinney CP
    Curr Opin Urol; 2004 Sep; 14(5):295-300. PubMed ID: 15300150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.
    Perrotte P; Matsumoto T; Inoue K; Kuniyasu H; Eve BY; Hicklin DJ; Radinsky R; Dinney CP
    Clin Cancer Res; 1999 Feb; 5(2):257-65. PubMed ID: 10037173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor biology (IMC-C225).
    Kim ES; Khuri FR; Herbst RS
    Curr Opin Oncol; 2001 Nov; 13(6):506-13. PubMed ID: 11673692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
    Harari PM; Huang SM
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
    Herbst RS; Langer CJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
    Normanno N; Maiello MR; De Luca A
    J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.
    Morales-Barrera R; Suárez C; de Castro AM; Racca F; Valverde C; Maldonado X; Bastaros JM; Morote J; Carles J
    Cancer Treat Rev; 2016 Nov; 50():208-216. PubMed ID: 27743530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EGF receptor family as targets for cancer therapy.
    Mendelsohn J; Baselga J
    Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy in advanced urothelial carcinoma.
    Verdoorn BP; Kessler ER; Flaig TW
    Oncology (Williston Park); 2013 Mar; 27(3):219-26. PubMed ID: 23687793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.